Cure8 regulatory brief
People with longstanding ulcerative colitis face higher colorectal cancer risk; this project focuses on a specific immune/stromal cell population (ST2+ cells responding to IL-33) that may help explain how chronic inflammation promotes colitis-associated cancer and could reveal new biomarkers or targets.
Researchers studying IBD-associated cancer, basic immunology and tumor microenvironment; clinicians interested in CAC risk and surveillance; patients and advocates tracking research on UC-to-CAC mechanisms.
The R21 project will use two mouse models (AOM/DSS and Winnie) and examine human CAC polyps to (1) phenotype ST2+ subepithelial cells that localize to polyps and test their ex vivo functions, and (2) determine the in vivo role these polyp-associated ST2+ cells play in CAC development.
The investigators justify animal use because polyposis and tumor microenvironment interactions cannot be fully modeled in cell culture. The study is exploratory and funded as a mechanistic project rather than a clinical trial; outcomes will be preclinical characterization and functional tests in animal models and human tissue samples.
The investigators propose that these unique IL-33-responsive cells could become diagnostic or therapeutic targets if subsequent work supports their role in tumorigenesis.
This record is a funded NIH R21 project (preclinical, exploratory). It describes planned animal experiments and analysis of human polyp tissue; it is not reporting clinical results. As a project record on NIH Reporter, details reflect the funded aims and rationale rather than peer-reviewed study findings.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The review brings together evidence that genetics, immune responses, the gut microbiome, and environmental triggers interact to cause Crohn's disease and ulcerative colitis.
A validated AI biomarker that predicts which IBD treatments are likely to work could reduce trial-and-error in treatment choices, potentially shortening time to effective therapy for people with Crohn's disease or...
Genetic ancestry can influence IBD risk and disease course, and most prior studies focused on European populations.
